Intestinal toxicity of non-steroidal anti-inflammatory drugs with differential cyclooxygenase inhibition selectivity.
The present study was designed to investigate the gastrointestinal side effects of cycloxygenase (COX) inhibitor with varying selectivity, called the non-steroidal antiinflammatory drugs (NSAIDs) viz., non-selective COX-1 & 2 inhibitor--aspirin, prefentially selective COX-2 inhibitor--nimesulide and highly selective COX-2 inhibitor-celecoxib. Treatment with NSAIDs exhibited a decrease in the activity of rat intestinal brush border membrane associated enzymes such as sucrase, lactase, maltase and alkaline phosphatase as compared to the control in the duodenum, jejunum and ileum. The uptake of D-glucose and L-histidine in the everted intestinal sac was found to be decreased. Also the decease of glucose and histidine uptake was found to be dependent on the substrate concentration, temperature and the time interval of incubation. The physical state and composition of brush border membrane was found to be altered as evident in the FTIR spectrum, by appearance of new peaks while disappearance of certain peaks occurred which were characteristics of the control membrane. The changes in wave number as well as peaks height were also noticed. Alterations in protein profile of the membrane were demonstrated using SDS-PAGE analysis where disappearance of few bands and change in the relative intensities of the bands were noticed and correlated with the alterations that have taken place at the molecular level. Histological studies have depicted a marked decrease in the absorption surface area such as the villi height of the intestinal segment. In addition, crypt number also deceased in the treated animals, an indication that such changes also correlate well with the changes in the transport of the end product nutrients.
Chopra
S
S
Department ofBiophyisics, Panjab University, Chandigarth-160014, India.
Saini
R Kishore
RK
Sanyal
S Nath
SN
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D001241:Aspirin / Q000633:toxicity*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000633:toxicity*; D004591:Electrophoresis, Polyacrylamide Gel; D005947:Glucose / Q000493:pharmacokinetics; D006639:Histidine / Q000493:pharmacokinetics; D006801:Humans; D007413:Intestinal Mucosa / Q000737:chemistry / Q000187:drug effects* / Q000648:ultrastructure; D007421:Intestine, Small / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D008871:Microvilli / Q000187:drug effects / Q000201:enzymology; D011720:Pyrazoles / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D017550:Spectroscopy, Fourier Transform Infrared; D013379:Substrate Specificity; D013449:Sulfonamides / Q000633:toxicity*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D006639:Histidine; D005947:Glucose; D000068579:Celecoxib; D001241:Aspirin; C012655:nimesulide